Impact of genomic aberrations and additional therapies on survival outcomes of patients with operable non-small cell lung cancer (NSCLC) from the NEOSTAR study.

Nicolas Zhou,Boris Sepesi,Cheuk Hong Leung,Heather Lin,William N. William,Annikka Weissferdt,Apar Pataer,Myrna C.B. Godoy,Frank V. Fossella,George R. Blumenschein,Xiuning Le,Anne S. Tsao,Jianjun Zhang,Wayne L. Hofstetter,Stephen G. Swisher,Ara A Vaporciyan,J. Jack Lee,Don L. Gibbons,John V. Heymach,Tina Cascone

Impact of genomic aberrations and additional therapies on survival outcomes of patients with operable non-small cell lung cancer (NSCLC) from the NEOSTAR study.

2021

8542Background: The NEOSTAR study compared nivolumab (N) vs. nivolumab plus ipilimumab (NI) with major pathological response (MPR; ≤10% viable tumor) as primary outcome. We report updated rates of ...

Keywords:

Medicine
Internal medicine
Ipilimumab
Nivolumab
primary outcome
Oncology
non-small cell lung cancer (NSCLC)
pathological response

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations